AmpliSeq for Illumina Comprehensive Panel v3

AmpliSeq for Illumina Comprehensive Panel v3

The AmpliSeq for Illumina Comprehensive Panel v3 enables the use of targeted resequencing to study somatic mutations across 161 genes with known associations to cancer. The Comprehensive Panel v3 is part of a streamlined workflow that includes AmpliSeq for Illumina PCR-based library preparation, Illumina sequencing by synthesis (SBS) next-generation sequencing (NGS) technology, and automated analysis. Library Prep requires as little as 1 ng high-quality DNA and RNA or 10 ng DNA and RNA from FFPE tissue. The DNA and RNA workflow of the Comprehensive Panel v3 workflow allows the analysis for SNVs, indels, CNVs, and gene fusions.

Panel:
20019109 AmpliSeq for Illumina Comprehensive Panel v3, 24 Reactions
Library Prep:
20019101 AmpliSeq for Illumina Library PLUS, 24 Reactions
20019102 AmpliSeq for Illumina Library PLUS, 96 Reactions
20019103 AmpliSeq for Illumina Library PLUS, 384 Reactions
Indexes:
20019105 AmpliSeq for Illumina CD Indexes Set A, 96 Indexes, 96 Reactions
Project Recommendations
Species Compatibility Human
Recommended Illumina Instrument* MiniSeq MiSeq NextSeq
Recommended Samples per run† High Output v3 Mid Output High Output
3 3 16 48
Max Recommended Read Length 2×150
Recommended Secondary Analysis DNA Amplicon App, DNA Amplicon Module, RNA Amplicon App, RNA Amplicon Module
Recommended Down Stream Analysis Variant Interpreter

* Library prep is compatible with all Illumina instruments. Recommended instruments chosen based on typical output and analysis need for selected application.

† Assumes minimum coverage of 500×

Order Now Support Data Sheet

Please rotate your device for details

For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see emea.illumina.com/company/legal.html.

© 2025 Illumina, Inc. All rights reserved.